Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-Cell Barcoded Lineage Tracing using KP4 PDA Cell Line - Pre and Post Drug Treatment with Trametinib

ABSTRACT: The KP4 PDA cell line (Untreated, DMSO-Treated and Trametinib-Treated) was used to experimentally assess plasticity between MAPK-Positive and MAPK-Negative states of Pancreatic Malignant Cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE292402 | GEO | 2026/01/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single-Cell Barcoded Lineage Tracing in KP4 PDA Cell Line

Project description:The KP4 PDA cell line was used to experimentally assess cross-lineage plasticiyty between different states of Pancreatic Malignant Cells

2026-01-16 | GSE268229 | GEO

Human PDA Cell Lines: single cell RNA-Sequencing after treatment with Trametinib (TRAM) and/or Hydroxychloroquine (HCQ)

Project description:Several Human PDA Cell Lines (ASPC1, PANC1, KP4, HPAFII, PATU8988S, PK45H, S2013, CAPAN1, BXPC3, HPAC, SW1990, MIAPACA2) were cultured and treated with DMSO, Trametinib (TRAM), Hydroxychloroquine (HCQ) and the combination of them before being prepared for Single-Cell RNA Sequencing

2026-01-16 | GSE310584 | GEO

Multi-ome profiles of KP4 cells, a Pancreatic Ductal adenocarcinoma cell line

Project description:Cells from the KP4 cell line were subjected to single-cell ATAC-seq and scRNA-seq to question whether the PDA MAPK positive and negative states represent stable and epigenetically distinct cell states.

2026-01-16 | GSE312315 | GEO

Single-Cell Barcoded Lineage Tracing in HS766T PDA Cell Line

Project description:The HS766T PDA cell line was used to experimentally assess cross-lineage plasticiyty between different states of Pancreatic Malignant Cells

2026-01-16 | GSE268077 | GEO

Single-Cell Barcoded Lineage Tracing in PATU8988S PDA Cell Line

Project description:The PATU8988S PDA cell line was used to experimentally assess cross-lineage plasticiyty between different states of Pancreatic Malignant Cells

2026-01-16 | GSE268441 | GEO

TF overexpression assay in PDA cell lines (Bulk RNA-Seq)

Project description:In this study the top Lineage Master Regulators of PDA were overexpressed in the KP4 Morphogenic cell line to study their reprogramming effect

2026-01-16 | GSE161368 | GEO

In Vivo pooled CRISPRko screens in PDA Cell Lines

Project description:We tested the essentiality of PDA state-specific Master Regulators in vivo by transducing a sgRNA library targeting 93 regulatory proteins into Cas9 expressing KP4 and HPAFII human cell lines. Cells were then injected into immunocompromised mice for genomic sequencing.

2026-01-16 | GSE270853 | GEO

Human PDA Cell Lines: single cell RNA-Sequencing in nomral versus serum-free media

Project description:Six Human PDA Cell Lines (KP4, Miapaca2, Panc1, Patu8902, PK45H, SW1990) were cultured in both normal and serum-free media conditions and then were subjected to Single-Cell RNA Sequqncing.

2026-01-16 | GSE266034 | GEO

Melanoma cell lines treated with dabrafenib ± trametinib

Project description:Rapid resistance to BRAF inhibitors in BRAFV600-mutant metastatic melanoma has produced an urgent need for new treatment options. BRAF inhibitor resistance commonly involves reactivation of mitogen-activated protein kinase (MAPK) signaling and yet inhibition of downstream kinases has not circumvented resistance, partly because MAPK is regulated via a complex network of feedback mechanisms that influence pathway rebound. To examine the transcriptome responses of melanoma cells to MAPK inhibition, a panel of 11 BRAFV600-mutant melanoma cell lines were treated with control (DMSO), 100nM dabrafenib alone (i.e BRAF inhibitor monotherapy) or 100nM dabrafenib + 10nM trametinib (i.e combination BRAF + MEK inhibition) for 24h.

2017-09-20 | GSE98314 | GEO

Predominance of MAPK reactivation in early resistance to debrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma.

Project description:One third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within six months. Treatment options for these patients remain limited. Here we analyse twenty BRAFV600 mutant melanoma metastases derived from 10 patients treated with the combination of debrafenib and trametinib for resistance mechanisms and genetic correlates of response. Resistance mechanisms are identified in 9/11 progressing tumors and MAPK reactivation occurred in 9/10 tumors, commonly via BRAF amplification and mutations activating NRAS and MEK2. Our data confirming that MEK2C125S, but not the synonymous MEK1C121S protein confers resistance to combination therapy, highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas. Exome sequencing did not identify additional progression-specific resistance candidates. Nevertheless, most melanomas carried additional oncogenic mutations at baseline (e.g. RCA1 and AKT3) that activate the MAPK and P13K pathways and are thus predicted to diminish response to MAPK inhibitors. Total RNA obtained from fresh frozen melanoma tumors treated with a combination of dabrafenib and trametinib

2014-12-03 | E-GEOD-61992 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data